Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Carbonxt Group - September 2022 Quarterly Activities Report (ASX:CG1)

Highlights -- Quarterly customer receipts of A$5.1m (prior quarter: A$4.1m) – a 19% quarter-on-quarter increase reflecting strong product demand. -- Operating cashflow positive quarter (A$...read more

Careteq Q1-FY23 activities report and appendix 4C (ASX:CTQ)

Highlights: -- Assistive Living Technology revenues on track for solid growth in FY23 as Careteq secures 8 new customers in Q1 and expands sales pipeline to >$5M -- Careteq wins first Strong ...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Japan patent office grants patent covering CLTX CAR T Dr Jason B Litten appointed as CMO Cassandra Harrison appointed as VP, Clinical Operations and Data Management ...read more

Carbonxt Group - Extension of Share Purchase Plan Closing Date (ASX:CG1)

Carbonxt Group Ltd (ASX:CG1) (‘‘Carbonxt” or “the Company”) would like to advise shareholders that the closing date for the Share Purchase Plan (SPP) announced on 30 Se...read more

Carbonxt Group - Supply contract with US customer extended until 2030 (ASX:CG1)

United States focused Cleantech company Carbonxt Group Ltd (ASX:CG1) (‘‘Carbonxt” or “the Company”) is pleased to announce the renewal and extension of its longsta...read more

Carbonxt Group - Share Purchase Plan Offer Booklet (ASX:CG1)

United States focused Cleantech company Carbonxt Group Ltd (ASX:CG1) (‘‘Carbonxt” or “the Company”) is pleased to provide existing eligible shareholders with the opport...read more

Carbonxt Group - Reinstatement to Quotation (ASX:CG1)

For more information, download the attached PDF.

Carbonxt Group - Proposed issue of securities (ASX:CG1)

For more information, download the attached PDF.

Carbonxt Group - Two Tranche Placement Raises $7M (ASX:CG1)

Carbonxt raises ~$1.3 million through a placement of ~13.1 million shares at $0.10 per share issued under current placement capacity Commitments received for a further ~$5.7 mi...read more

Carbonxt Group - Request for extension to voluntary suspension (ASX:CG1)

Carbonxt Group Limited ACN 097 247 464 (CG1 or the Company) requests an extension to the voluntary suspension of quotation of its ordinary shares in accordance with ASX Listing Rule 17.2, pending an...read more

Carbonxt Group - Suspension from Quotation (ASX:CG1)

The securities of Carbonxt Group Limited (‘CG1’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of CG1, pending the release of an announcement regar...read more

Carbonxt Group - Trading Halt (ASX:CG1)

The securities of Carbonxt Group Limited (‘CG1’) will be placed in trading halt at the request of CG1, pending it releasing an announcement. Unless ASX decides otherwise, the securities ...read more

Chimeric Therapeutics - Appendix 4E and Preliminary Final Report (ASX:CHM)

To view the Appendix and Preliminary Financial Report, download the attached PDF.

Carbonxt Group - Ceasing to be a substantial holder (ASX:CG1)

To view the Notice of ceasing to be a substantial holder, download the attached PDF.

Carbonxt Group - Appendix 4E and Annual Report (ASX:CG1)

To view the Appendix, download the attached PDF.

Viewing: 91 - 105 of 200 Previous | Next